Impact of smoking on long-term outcomes in patients with atherosclerotic vascular disease treated with aspirin or clopidogrel: Insights from the CAPRIE trial (clopidogrel versus aspirin in patients at risk of ischemic events)

Journal of the American College of Cardiology

Volumn 63, Issue 8, 2014, Pages 769-777

  Ferreiro, José L ^a,b   Bhatt, Deepak L ^c   Ueno, Masafumi ^a   Bauer, Deborah ^d   Angiolillo, Dominick J ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c HARVARD MEDICAL SCHOOL   (United States)

^d SANOFI   (France)

Author keywords

antiplatelet agents; clopidogrel; smoking; smoking paradox

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL;

ADULT; ARTICLE; ATHEROSCLEROSIS; BLEEDING DISORDER; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CAUSE OF DEATH; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; FEMALE; HEART DEATH; HEART INFARCTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POST HOC ANALYSIS; PRIORITY JOURNAL; SMOKING; SMOKING HABIT; ATHEROSCLEROTIC VASCULAR DISEASE; BLEEDING; DEATH; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); VASCULAR DISEASE;

ANTIPLATELET AGENTS; CLOPIDOGREL; SMOKING; SMOKING PARADOX;

ASPIRIN; ATHEROSCLEROSIS; BRAIN ISCHEMIA; FEMALE; HUMANS; MALE; RISK FACTORS; SINGLE-BLIND METHOD; SMOKING; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84896718806     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2013.10.043     Document Type: Article

References (39)

1. M.S. Faber, and U. Fuhr Time response of cytochrome P450 1A2 activity on cessation of heavy smoking Clin Pharmacol Ther 76 2004 178 184 (Pubitemid 39013407)
2. S. Zevin, and N.L. Benowitz Drug interactions with tobacco smoking. An update Clin Pharmacokinet 36 1999 425 438 (Pubitemid 29317490)
3. E.R. Bates, W.C. Lau, and D.J. Angiolillo Clopidogrel-drug interactions J Am Coll Cardiol 57 2011 1251 1263
4. I. Washio, M. Maeda, and C. Sugiura et al. Cigarette smoke extract induces CYP2B6 through constitutive androstane receptor in hepatocytes Drug Metab Dispos 39 2011 1 3
5. A.M. Yousef, T. Arafat, N.R. Bulatova, and R. Al-Zumyli Smoking behaviour modulates pharmacokinetics of orally administered clopidogrel J Clin Pharm Ther 33 2008 439 449
6. W. Hochholzer, D. Trenk, and J.L. Mega et al. Impact of smoking on antiplatelet effect of clopidogrel and prasugrel after loading dose and on maintenance therapy Am Heart J 162 2011 518-26.e5
7. K.P. Bliden, J. Dichiara, and L. Lawal et al. The association of cigarette smoking with enhanced platelet inhibition by clopidogrel J Am Coll Cardiol 52 2008 531 533
8. T. Gremmel, S. Steiner, D. Seidinger, R. Koppensteiner, S. Panzer, and C.W. Kopp Smoking promotes clopidogrel-mediated platelet inhibition in patients receiving dual antiplatelet therapy Thromb Res 124 2009 588 591
9. M. Ueno, J.L. Ferreiro, and B. Desai et al. Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study J Am Coll Cardiol Intv 5 2012 293 300
10. Z. Motovska, P. Widimsky, and R. Petr et al. Factors influencing clopidogrel efficacy in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention: statin's advantage and the smoking "paradox" J Cardiovasc Pharmacol 53 2009 368 372
11. J.H. Cho, Y.H. Jeong, and Y.J. Ahn et al. The impact of smoking on post-clopidogrel platelet reactivity in patients with acute myocardial infarction Korean Circ J 40 2010 119 124
12. Y.H. Jeong, J.H. Cho, and M.K. Kang et al. Smoking at least 10 cigarettes per day increases platelet inhibition by clopidogrel in patients with ST-segment-elevation myocardial infarction Thromb Res 126 2010 e334 e338
13. N.R. Desai, J.L. Mega, S. Jiang, C.P. Cannon, and M.S. Sabatine Interaction between cigarette smoking and clinical benefit of clopidogrel J Am Coll Cardiol 53 2009 1273 1278
14. F.S. Salek Relationship between clopidogrel and cigarette smoking status in patients with acute coronary syndromes without ST-segment elevation myocardial infarction (abstr) Pharmacotherapy 30 2010 154e
15. K.Y. Saraff, S.R. Steinhubl, A.P. Hsu, and E.J. Topol Smoking influences the effectiveness of dual antiplatelet therapy on long-term outcomes following percutaneous coronary intervention (abstr) J Am Coll Cardiol 47 2006 36B
16. J.S. Berger, D.L. Bhatt, and S.R. Steinhubl et al. Smoking, clopidogrel, and mortality in patients with established cardiovascular disease Circulation 120 2009 2337 2344
17. P.A. Gurbel, T.D. Nolin, and U.S. Tantry Clopidogrel efficacy and cigarette smoking status JAMA 307 2012 2495 2496
18. J.J. Gagne, K. Bykov, N.K. Choudhry, T.J. Toomey, J.G. Connolly, and J. Avorn Effect of smoking on comparative efficacy of antiplatelet agents: systematic review, meta-analysis, and indirect comparison BMJ 347 2013 f5307
19. Z.G. Zhao, M. Chen, and Y. Peng et al. The impact of smoking on clinical efficacy and pharmacodynamic effects of clopidogrel: a systematic review and meta-analysis Heart 100 2014 192 199
20. CAPRIE Steering Committee A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) Lancet 348 1996 1329 1339
21. L.A. Harker, J.P. Boissel, A.J. Pilgrim, M. Gent CAPRIE Steering Committee and Investigators Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE Drug Saf 21 1999 325 335 (Pubitemid 29465699)
22. P.A. Ringleb, D.L. Bhatt, A.T. Hirsch, E.J. Topol, W. Hacke Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events Investigators Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events Stroke 35 2004 528 532 (Pubitemid 38174442)
23. S.C. Smith Jr., E.J. Benjamin, and R.O. Bonow et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation J Am Coll Cardiol 58 2011 2432 2446
24. H.K. Koh, and K.G. Sebelius Ending the tobacco epidemic JAMA 308 2012 767 768
25. S.D. Wiviott, E. Braunwald, and C.H. McCabe et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015 (Pubitemid 350106708)
26. L. Wallentin, R.C. Becker, and A. Budaj et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 2009 1045 1057
27. J.H. Cornel, R.C. Becker, and S.G. Goodman et al. Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes - insights from the PLATelet inhibition and patient Outcomes (PLATO) trial Am Heart J 164 2012 334 342
28. P.A. Gurbel, K.P. Bliden, and D.K. Logan et al. The influence of smoking status on the pharmacodynamics of prasugrel and clopidogrel: the PARADOX study J Am Coll Cardiol 62 2013 505 512
29. M.T. Roe, P.W. Armstrong, and K.A. Fox et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization N Engl J Med 367 2012 1297 1309
30. J.H. Cornel, M. Ohman, and B. Neely et al. Impact of smoking status on clinical outcomes with prasugrel versus clopidogrel in patients with acute coronary syndromes managed without revascularization: insights from the TRILOGY ACS trial (abstr) J Am Coll Cardiol 61 Suppl 10 2013
31. G. Shanker, J.L. Kontos, and D.M. Eckman et al. Nicotine upregulates the expression of P2Y12 on vascular cells and megakaryoblasts J Thromb Thrombolysis 22 2006 213 220 (Pubitemid 44857783)
32. D.L. Bhatt, K.A. Fox, and W. Hacke et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events N Engl J Med 354 2006 1706 1717
33. D.L. Bhatt, S.P. Marso, A.T. Hirsch, P.A. Ringleb, W. Hacke, and E.J. Topol Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus Am J Cardiol 90 2002 625 628 (Pubitemid 35264538)
34. D.J. Angiolillo, A. Fernandez-Ortiz, and E. Bernardo et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives J Am Coll Cardiol 49 2007 1505 1516 (Pubitemid 46517957)
35. J.L. Ferreiro, and D.J. Angiolillo Clopidogrel response variability: current status and future directions Thromb Haemost 102 2009 7 14
36. K.W. Park, S.H. Kang, and J. Kang et al. Enhanced clopidogrel response in smokers is reversed after discontinuation as assessed by VerifyNow assay: additional evidence for the concept of 'smokers' paradox' Heart 98 2012 1000 1006
37. K.W. Park, J.J. Park, and K.H. Jeon et al. Enhanced clopidogrel responsiveness in smokers: smokers' paradox is dependent on cytochrome P450 CYP1A2 status Arterioscler Thromb Vasc Biol 31 2011 665 671
38. P. Henry, A. Vermillet, and B. Boval et al. 24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease Thromb Haemost 105 2011 336 344
39. J.W. Eikelboom, G.J. Hankey, and J. Thom et al. Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk Circulation 118 2008 1705 1712